跳转至内容
Merck
CN

SML2073

(R)-9bMS

≥98% (HPLC)

别名:

(R)-5-Chloro-N-[4-(4-methylpiperazin-1-yl)phenyl]-N′-[(tetrahydrofuran-2-yl)methyl]pyrimidine-2,4-diamine mesylate, (R)-9b mesylate, 5-Chloro-N2-[4-(4-methyl-1-piperazinyl)phenyl]-N4-[[(2R)-tetrahydro-2-furanyl]methyl]-2,4-pyrimidinediamine

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C21H31ClN6O4S
化学文摘社编号:
分子量:
499.03
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

C[N+](CC1)([H])CCN1C(C=C2)=CC=C2NC3=NC(NC[C@@H]4OCCC4)=C(Cl)C=N3.CS(=O)([O-])=O

InChI

1S/C20H27ClN6O.CH4O3S/c1-26-8-10-27(11-9-26)16-6-4-15(5-7-16)24-20-23-14-18(21)19(25-20)22-13-17-3-2-12-28-17;1-5(2,3)4/h4-7,14,17H,2-3,8-13H2,1H3,(H2,22,23,24,25);1H3,(H,2,3,4)/t17-;/m1./s1

InChI key

XUIDATLQOQYHBD-UNTBIKODSA-N

Biochem/physiol Actions

(R)-9bMS is a potent and selective inhibitor of ACK1 (TNK2) tyrosine kinase that exhibits potent anticancer activity. (R)-9bMS attenuates AR and AR-V7 expression in prostate cancer cells. (R)-9bMS potently inhibits triple negative breast cancer (TNBC) cells proliferation.
potent and selective inhibitor of ACK1 (TNK2) tyrosine kinase that exhibits potent anticancer activity


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Harshani R Lawrence et al.
Journal of medicinal chemistry, 58(6), 2746-2763 (2015-02-24)
The tyrosine kinase ACK1, a critical signal transducer regulating survival of hormone-refractory cancers, is an important therapeutic target, for which there are no selective inhibitors in clinical trials to date. This work reports the discovery of novel and potent inhibitors
Kiran Mahajan et al.
Cancer cell, 31(6), 790-803 (2017-06-14)
The androgen receptor (AR) is critical for the progression of prostate cancer to a castration-resistant (CRPC) state. AR antagonists are ineffective due to their inability to repress the expression of AR or its splice variant, AR-V7. Here, we report that
Xinyan Wu et al.
Oncotarget, 8(2), 2971-2983 (2016-12-03)
Breast cancer is the most prevalent cancer in women worldwide. About 15-20% of all breast cancers do not express estrogen receptor, progesterone receptor or HER2 receptor and hence are collectively classified as triple negative breast cancer (TNBC). These tumors are



全球贸易项目编号

货号GTIN
SML2073-5MG04061833248027
SML2073-25MG04061833248010